Analysts Conflictied on These Healthcare Names: Voyager Therapeutics Inc (NASDAQ: VYGR), Biocept Inc (NASDAQ: BIOC) and BioDelivery (NASDAQ: BDSI)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics Inc (NASDAQ: VYGR), Biocept Inc (NASDAQ: BIOC) and BioDelivery (NASDAQ: BDSI).

Voyager Therapeutics Inc (NASDAQ: VYGR)

In a report released today, Phil Nadeau from Cowen & Co. reiterated a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR). The company’s shares opened today at $12.70.

Nadeau noted:

“VYGR had a 9/30 cash balance of $191.2MM, which we project will fund operations.”

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 2.4% and a 48.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Lexicon Pharmaceuticals.

Voyager Therapeutics Inc has an analyst consensus of Moderate Buy.

Biocept Inc (NASDAQ: BIOC)

Roth Capital analyst Chris Lewis reiterated a Buy rating on Biocept Inc (NASDAQ: BIOC) today and set a price target of $1.60. The company’s shares opened today at $0.84.

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 3.7% and a 54.8% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Natus Medical Inc.

Biocept Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.60.

BioDelivery (NASDAQ: BDSI)

Cantor Fitzgerald analyst Chiara Russo reiterated a Hold rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $3. The company’s shares opened today at $1.95, close to its 52-week low of $1.70.

Russo noted:

“Bracing for Cuts: BDSI reported a 3Q16 loss of ($0.30) with product revenue of $2.0M, total revenue of $3.6M. EPS was in line with Cantor estimate of ($0.28), as were revenue estimates. Though management reiterated its $20M cost-cutting strategy through YE17, OpEx was flat QoQ at ~$16.5M. BDSI finished the quarter with $44.7M, which we estimate will fund operations through 3Q17. We have adjusted our estimates to reflect 3Q results and additional revenue updates. One Quarter Down, Five to Go: Management reiterated its focus on bringing Bunavail to profitability by YE17, which requires 4,200 weekly RXs, with revenue/script at levels of ~$74.”

According to TipRanks.com, Russo is a 1-star analyst with an average return of -1.2% and a 46.9% success rate. Russo covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Axsome Therapeutics Inc, and Flexion Therapeutics.

BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $4.